Trimethylamine N-Oxide Generated by the Gut Microbiota: Potential Atherosclerosis Treatment Strategies

Area of Science:

• Microbiology
• Cardiology
• Metabolomics

Background:

• Cardiovascular diseases (CVD) represent a significant global health burden, with atherosclerotic CVD (AS) being a major cause of mortality.
• Gut microbiota metabolites, particularly trimethylamine-N-oxide (TMAO), are increasingly recognized as crucial players in the development of AS.
• TMAO is identified as an independent risk factor for CVD, highlighting its pathogenic role in AS.

Approach:

• This review examines the intricate relationship between TMAO and atherosclerosis.
• It focuses on emerging therapeutic strategies targeting TMAO and its metabolic pathways.
• Potential interventions discussed include dietary modifications, gut microbiota modulation, liver enzyme activity suppression, and renal function enhancement.

Key Points:

• TMAO, produced by gut microbes, is a critical mediator in the pathogenesis of atherosclerosis.
• Interventions aimed at reducing TMAO levels show promise as novel therapeutic strategies for AS.
• Multi-faceted approaches, including diet, microbiota, and organ function management, are being explored.

Conclusions:

• Targeting TMAO metabolism presents a promising avenue for developing effective and cost-efficient treatments for AS.
• Understanding TMAO's role opens new possibilities for preventing and managing cardiovascular diseases.
• Further research into TMAO pathways can lead to innovative clinical interventions for atherosclerotic conditions.